Schizophrenia Research
Volume 119, Issue 1 , Pages 101-109 , June 2010

Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

  • Julio Bobes

      Affiliations

    • Department of Medicine, Psychiatry Area, University of Oviedo, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo, Asturias, Spain
    • Corresponding Author InformationCorresponding author. Departamento de Medicina, Facultad de Medicina, Universidad de Oviedo, c/Juan Clavería, 6, 33006 Oviedo, Asturias, Spain. Tel./fax: +34 985 10 35 53.
    • ,
  • Celso Arango

      Affiliations

    • Department of Psychiatry, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
    • ,
  • Margarida Garcia-Garcia

      Affiliations

    • Department of Operations, Biometria Clínica CRO, Barcelona, Spain
    • ,
  • Javier Rejas

      Affiliations

    • Health Outcomes Research Department, Medical Unit, Pfizer España, Alcobendas, Madrid, Spain

Received 11 November 2009 ,Revised 5 February 2010 ,Accepted 6 February 2010.

References 

  1. Aguilar MC, Gurpegui M, Diaz FJ, de Leon J. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br. J. Psychiatry. 2005;186:215–221
  2. American Diabetes Association. Consensus Development Conference on Antipsychotics Drugs and Obesity and Diabetes. Diabetes Care. 2004;27:596–601
  3. Baker A, Richmond R, Castle D, Kulkarni J, Kay-Lambkin F, Sakrouge R, et al. Coronary heart disease risk reduction intervention among overweight smokers with a psychotic disorder: pilot trial. Aust. NZ J. Psychiatry. 2009;43:129–135
  4. Barnett AH, Mackin P, Chaudhry I, et al. Missing metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J. Psychopharmacol. 2007;21:357–373
  5. Barr AM, Procyshyn RM, Hui P, Johnson JL, Honer WG. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr. Res. 2008;100:252–260
  6. Bobes J, Arango C, Aranda P, Carmena R, García-García M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr. Res. 2007;90:162–173
  7. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res. 2003;62(1–2):77–88
  8. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry. 2000;177:212–217
  9. Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aus. N. Z. J. Psychiatry. 2009;43:277–282
  10. Cohn T, Prud´homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry. 2004;49:753–760
  11. Conley RR, Shim JC, Kelly DL, Feldman S, Yu Y, McMahon RP. Cardiovascular disease in relation to weight in deceased persons with schizophrenia. Compr. Psychiatry. 2005;46:460–467
  12. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry. 2009;24:412–424
  13. De Leon J. Smoking and vulnerability for schizophrenia. Schizophr. Bull. 1996;22:405–409
  14. De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr. Res. 2005;76:135–157
  15. De Leon J, Susce MT, Diaz FJ, Rendon DM, Velásquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J. Clin. Psychiatry. 2005;66:1447–1455
  16. De Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007;92:95–102
  17. Dervaux A, Laqueille X. Smoking and schizophrenia: epidemiological and clinical features. Encephale. 2008;34:299–305
  18. Encuesta Nacional de Salud, 2006. Instituto Nacional de Estadística. http://www.ine.es/jaxi/menu.do?L=0&type=pcaxis&path=%2Ft15/p419&file=inebase. Access: March 13th, 2009).
  19. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J. Nerv. Ment. Dis. 2004;192:19–27
  20. Garcia-Portilla, M.P., Saiz, P.A., Benabarre, A., Florez, G., Bascaran, M.T., Díaz, E.M., Bousoño, M., Bobes, J., in press. Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatrica Scandinavica. doi:10.1111/j.1600-0447.2009.01498.x.
  21. Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. Prim Care Companion. J. Clin. Psychiatry. 2008;10:52–58
  22. Gonzalez-Pinto A, Gutiérrez M, Ezcurra J, Aizpuru F, Mosquera F, Lopez P, et al. Tobacco smoking and bipolar disorder. J. Clin. Psychiatry. 1998;59:225–228
  23. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am. J. Ther. 2003;10:348–355
  24. Guy W. Early Clinical Drug Evaluation (ECDEU). Assessment Manual. Rockville: Nat. Inst. Ment. Helth; 1976;
  25. Hiroeh U, Appleby L, Mortensen PB, Dunn G. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet. 2001;358:2110–2112
  26. Holt RI. Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br. J. Psychiatr., Suppl. 2005;47:S55–S63
  27. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 1986;143:993–997
  28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  29. Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr. Bull. 2009;
  30. Kirkpatrick B. The concept of schizophrenia. Rev. Psiquiatr. Salud. Ment. 2009;2:105–107
  31. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical anti psychotic drugs. J. Clin. Psychiatry. 2004;65:702–706
  32. McDermott S, Moran R, Platt T, et al. Heart disease, schizophrenia and affective psychoses: epidemiology of risk in primary care. Community Ment. Health J. 2005;41:747–755
  33. Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res. 2003;117:127–135
  34. Osborn DP, Nazareth I, King MB. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: a cross sectional study in primary care. Soc. Psychiatry Psychiatr. Epidemiol. 2007;42:787–793
  35. Poirier MF, Canceil O, Baylé F, Millet B, Bourdel MC, Moatti C, et al. Prevalence of smoking in psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26:529–537
  36. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966Birth Cohort study. J. Clin. Psychiatry. 2005;66:559–563
  37. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry. 2002;159:561–566
  38. von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr. Scand. Suppl. 2009;438:15–21
  39. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1988;97:1837–1847
  40. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J. Clin. Psychiatry. 2004;65(Suppl 18):13–26
  41. Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann. Intern. Med. 2010;152:10–17

PII: S0920-9964(10)01116-3

doi: 10.1016/j.schres.2010.02.1030

Schizophrenia Research
Volume 119, Issue 1 , Pages 101-109 , June 2010

Article Tools

* Image Usage & Resolution